Breast cancer - Loss of PTEN predicts resistance to treatment

New England Journal of Medicine

Volumn 351, Issue 22, 2004, Pages 2337-2338

  Pandolfi, Pier Paolo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P85; RAPAMYCIN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; DRUG RESISTANCE; GENE DOSAGE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; HUMANS; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 9244219598     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcibr043143     Document Type: Article

References (5)

1. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-90.
2. Nagata Y, Lan K-H, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.
3. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115-21.
4. Trotman LC, Niki M, Dotan Z, et al. Pten dose dictates cancer progression. PLoS Biol 2003;1(3):E59.
5. Stephens P, Hunter C, Bignell G, et al. Intragenic ERBB2 kinase mutations in tumors. Nature 2004;431:525-6.